SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC)

Authors :: J. Lambea
J. J. Garcia
B. Pérez-Valderrama
Á. Rodríguez Sánchez
M.T. Abad Villar
Jose-Luis Gonzalez-Larriba
E.M. Fernandez Parra
J.A. Arranz Arija
E. Gallardo Diaz
Javier Cassinello
J.L. Puertas Álvarez
O. Etxaniz Ulazia
J.A. Virizuela Echaburu
M. Constenla Figueiras
M.J. Mendez Vidal
A. Pinto Marin
J.J. Tafalla García
C. Maximiano Alonso
F.J. Vazquez Mazon
J.C. Villa Guzman
Source :: Annals of Oncology. 28:v313
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Everolimus
business.industry
First line
Hematology
Axitinib
Pazopanib
03 medical and health sciences
0302 clinical medicine
Second line
Internal medicine
Medicine
Metastatic renal carcinoma
030212 general & internal medicine
business
030217 neurology & neurosurgery
medicine.drug

Full Text Access

Tools